Prismaccess / Evalumade provide comprehensive overviews and specific country regulations and guidelines on HTA and reimbursement.
PrismHEOR implements, harmonizes and translates published data in economic evaluation and outcome research, allowing HEOR departments to retrieve trends and insights.
Dedicated to market access, HEOR and pricing departments, our platforms cover 27 regulation agencies worldwide and 20 years of data on 1,000 therapeutic areas, allowing to anticipate market access positioning and rely on secure and exhaustive data.
We are integrating AI and Machine learning to enhance the capabilities of our platforms.
Forecasts and screenings, accelerated search in hundreds of documents, real-time response to a given problem, extraction and analysis, our data will be processed with increased power.
The reimbursement policy of health authorities is becoming more restrictive with the increased number of innovative drugs introduced on the market.
With a fast process of large volumes of data, Prioritis is able to deliver deep analysis on specific criteria, essential for a successful assessment.
The key inputs managed by AI:
Our database covers all therapeutic areas from major HTA countries and is monitored and updated on a daily basis by our HTA experts.
Access immediately to key information to incorporate into your product or disease area landscape.
Search can be made by drug name, active ingredient, manufacturer, type of recommendation, therapeutic area. Our interface has been specifically built to facilitate downloads, data extraction and printing.
With PrismHEOR, Prioritis has extended its offering to include an overview of different decision-analytic assessments across multiple HTA markets.